EUVIMEDEUVIMED entdecken
Crossref

Therapeutic potential of 6BIO and DKK1-LRP6 inhibitor in Wnt/β-catenin pathway modulation for amyloid-β-induced Alzheimer's disease model

Manisha Prajapat, Phulen Sarma, Gurjeet Kaur, Gajendra Choudhary iD, Shaveta Jain, Raj Kamal, Omkar Bains, Namrata Sangwan, Ajay Prakash, Bikash Medhi iD

Journal of Alzheimer’s Disease · 2025-09 · 107 (2) · 857-878

DOI: 10.1177/13872877251362787 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, 2025-09. Verfasst von Manisha Prajapat und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Hauptthemen laut MEDLINE: Alzheimer Disease, Low Density Lipoprotein Receptor-Related Protein-6, Wnt Signaling Pathway, Intercellular Signaling Peptides and Proteins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 89 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The Wnt/β-catenin signaling pathway plays a crucial role in central nervous system development, with emerging evidence linking its dysregulation to the progression of Alzheimer's disease (AD).

Objective

This study investigates the activation of Wnt signaling by targeting GSK3β and the DKK1/LRP6 interaction using a combination of 6BIO (6Bromoindirubin-3-oxime) and a novel gallocyanine derivative (8e) modulator.

Methods

We identified the interaction energy scores of both modulators with target proteins through an in-silico approach. Furthermore, the effects of 6BIO (10 µM) and 8e (20 µM) were assessed in SH-SY5Y cells treated with Aβ 1–42 (20 µM). The efficacy of these modulators was also evaluated in male Wistar rats through dose-ranging studies. An Alzheimer's disease model was established via intracerebroventricular injection of Aβ 1–42 , followed by treatment with 6BIO (23.8 µg/kg/day, i.p.) and 8e (4.2 mg/kg/day, i.p.).

Results

Both modulators demonstrated favorable binding energy scores and dynamic simulation results against the targeted proteins. In Aβ 1–42 -treated SHSY5Y cells, the combination of 6BIO and 8e significantly reduced reactive oxygen species production and apoptotic activity while modulating protein expression. In vivo study, rats treated with combination of 6BIO and 8e modulators exhibited improved neurobehavioral activity compared to AD model rats, along with altered expression of DKK1, β-catenin, p-tau, and pGSK3β. Additionally, decreased oxidative stress and apoptosis markers.

Conclusions

These findings suggest that the combined targeting of GSK3β and LRP6 represents a promising therapeutic strategy for AD. The combination of 6BIO and 8e shows potential as a novel modulator and warrants further investigation in clinical trials to assess its therapeutic efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseLow Density Lipoprotein Receptor-Related Protein-6Wnt Signaling PathwayIntercellular Signaling Peptides and ProteinsAnimalsAmyloid beta-PeptidesHumansMaleRats, WistarRatsPeptide FragmentsDisease Models, AnimalCell Line, Tumor

Stichwörter der Autor:innen

Alzheimer's diseaseDKK1GSK3βWnt signalingamyloid-βtau protein

Substanzen

Amyloid beta-PeptidesLow Density Lipoprotein Receptor-Related Protein-6Peptide FragmentsIntercellular Signaling Peptides and Proteinsamyloid beta-protein (1-42)LRP6 protein, humanDKK1 protein, humanDkk1 protein, rat

Autor:innen und Institutionen

  • Department of Pharmacology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
  • Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Guwahati, India.
  • Department of Biochemistry, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
  • Kurukshetra University, Kurukshetra, India.
  • Department of Anesthesia, Stanford University, Stanford, CA, USA.

ORCID-Profile: Gajendra Choudhary, Bikash Medhi

Zitieren

APA

Prajapat, M., Sarma, P., Kaur, G., Choudhary, G., Jain, S., Kamal, R., Bains, O., Sangwan, N., Prakash, A., & Medhi, B. (2025). Therapeutic potential of 6BIO and DKK1-LRP6 inhibitor in Wnt/β-catenin pathway modulation for amyloid-β-induced Alzheimer's disease model. Journal of Alzheimer’s Disease, 107(2), 857-878. https://doi.org/10.1177/13872877251362787

Vancouver

Prajapat M, Sarma P, Kaur G, Choudhary G, Jain S, Kamal R, et al. Therapeutic potential of 6BIO and DKK1-LRP6 inhibitor in Wnt/β-catenin pathway modulation for amyloid-β-induced Alzheimer's disease model. Journal of Alzheimer’s Disease. 2025;107(2):857-878. doi:10.1177/13872877251362787

BibTeX
@article{Prajapat2025,
  author = {Prajapat, Manisha and Sarma, Phulen and Kaur, Gurjeet and Choudhary, Gajendra and Jain, Shaveta and Kamal, Raj and Bains, Omkar and Sangwan, Namrata and Prakash, Ajay and Medhi, Bikash},
  title = {Therapeutic potential of 6BIO and DKK1-LRP6 inhibitor in Wnt/β-catenin pathway modulation for amyloid-β-induced Alzheimer's disease model},
  journal = {Journal of Alzheimer’s Disease},
  year = {2025},
  volume = {107},
  number = {2},
  pages = {857--878},
  doi = {10.1177/13872877251362787}
}
Kostenlos starten →